ストックスクリーナーアプリを入手
332.92
0.51%
1.68
アフターアワーズ：
332.92
前日終値:
$331.24
開ける：
$331.24
24時間の取引高:
1.56M
Relative Volume:
1.03
時価総額：
$44.15B
収益：
$3.71B
当期純損益:
$313.75M
株価収益率:
147.50
EPS:
2.2571
ネットキャッシュフロー:
$465.38M
1週間 パフォーマンス:
-0.97%
1か月 パフォーマンス:
-6.15%
6か月 パフォーマンス:
-26.70%
1年 パフォーマンス:
+40.41%
1日の値動き範囲:
$328.39
$334.80
1週間の範囲:
$322.00
$341.38
52週間の値動き範囲:
$205.87
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
名前
Alnylam Pharmaceuticals Inc
セクター
電話
(617) 551-8200
住所
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY vs VRTX, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
332.92 | 43.93B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.83 | 121.97B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.67 | 81.49B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
766.92 | 47.74B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
316.99 | 35.67B | 4.98B | 69.60M | 525.67M | 0.5198 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-28 | 再開されました | Barclays | Overweight |
| 2026-01-07 | 再開されました | Oppenheimer | Outperform |
| 2025-08-04 | アップグレード | Oppenheimer | Perform → Outperform |
| 2025-08-04 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | 再開されました | Raymond James | Outperform |
| 2025-07-21 | 開始されました | Truist | Buy |
| 2025-03-31 | 開始されました | Redburn Atlantic | Buy |
| 2025-03-24 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-11-12 | ダウングレード | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-08-16 | アップグレード | Goldman | Neutral → Buy |
| 2024-02-16 | ダウングレード | Goldman | Buy → Neutral |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2023-12-08 | 開始されました | Wells Fargo | Equal Weight |
| 2023-10-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2023-09-29 | 開始されました | Raymond James | Outperform |
| 2023-05-05 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | 開始されました | SMBC Nikko | Neutral |
| 2023-03-21 | 開始されました | Bernstein | Outperform |
| 2023-01-18 | 開始されました | Canaccord Genuity | Buy |
| 2022-09-09 | 再開されました | Morgan Stanley | Equal-Weight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-06-27 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-06-07 | 開始されました | William Blair | Outperform |
| 2022-04-25 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | 開始されました | Citigroup | Buy |
| 2022-02-03 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-01-03 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | アップグレード | Goldman | Neutral → Buy |
| 2021-11-22 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-10-04 | アップグレード | UBS | Neutral → Buy |
| 2021-08-04 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-02-12 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-02-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-01-25 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | 再開されました | Berenberg | Hold |
| 2020-09-08 | 開始されました | Citigroup | Buy |
| 2020-08-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-05-13 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-04-24 | 再開されました | Evercore ISI | Outperform |
| 2020-03-19 | 開始されました | Berenberg | Buy |
| 2019-12-19 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-11-20 | 開始されました | Oppenheimer | Outperform |
| 2019-11-13 | 開始されました | BofA/Merrill | Buy |
| 2019-05-23 | 再開されました | Goldman | Neutral |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-03-06 | アップグレード | Evercore ISI | In-line → Outperform |
| 2019-03-05 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | 開始されました | UBS | Neutral |
| 2018-10-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-08-13 | 繰り返されました | Stifel | Buy |
| 2018-08-07 | アップグレード | Stifel | Hold → Buy |
| 2018-05-04 | 繰り返されました | Stifel | Hold |
| 2018-03-28 | 開始されました | Evercore ISI | In-line |
すべてを表示
Alnylam Pharmaceuticals Inc (ALNY) 最新ニュース
Alnylam’s New Phase 1 ALN-4285 Trial: What Early Safety Data Could Mean for ALNY Investors - TipRanks
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Westfield Capital Management Co. LP - MarketBeat
A Look At Alnylam Pharmaceuticals (ALNY) Valuation After Recent Share Price Pullback - simplywall.st
Alnylam Pharmaceuticals Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
TD Asset Management Inc Sells 128,660 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Why Alnylam Pharmaceuticals Stock Slipped Today - AOL.com
Reassessing Alnylam Pharmaceuticals (ALNY) After Recent Share Price Weakness - simplywall.st
Will Alnylam’s (ALNY) 2025 Profitability and $2.26 Billion Shelf Filing Redefine Its Risk Profile? - simplywall.st
Alnylam to Webcast Presentation at TD Cowen 46th Annual Health Care Conference - BioSpace
Here's How Much $100 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth Today - Benzinga
Understanding the Setup: (ALNY) and Scalable Risk - Stock Traders Daily
Fiera Capital Corp Grows Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
NewEdge Wealth LLC Buys 7,091 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
ANTIPODES PARTNERS Ltd Cuts Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Will Alnylam Pharmaceuticals Inc. stock benefit from automationTrade Risk Summary & High Return Stock Watch Alerts - mfd.ru
China Universal Asset Management Co. Ltd. Cuts Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals (ALNY) Reports $3B 2025 Revenue Driven by 151% TTR Franchise Surge - Insider Monkey
Assessing Alnylam Pharmaceuticals (ALNY) Valuation After First Profitable Year And Rapid Revenue Growth - simplywall.st
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Moderna (MRNA) and NewAmsterdam Pharma Company (NAMS) - The Globe and Mail
Shifting Trends in Biotechnology Mergers and Acquisitions - Intellectia AI
Regeneron Pharmaceuticals Inc. Lowers Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Rating Upgraded by Freedom Capital - MarketBeat
Oligonucleotide Therapy Market to hit US$ 40.16 Billion by 2033 | - openPR.com
RNAi Therapeutics Market to hit US$ 8.80 Billion by 2033 | North - openPR.com
11,700 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Bought by Alberta Investment Management Corp - MarketBeat
1 Reason I'd Buy Eli Lilly Stock and Never Sell - AOL.com
Analysts Trim Alnylam Pharmaceuticals, Inc. (ALNY) Targets but Keep Faith in 2026 Growth - Finviz
Alnylam Pharmaceuticals' (ALNY) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
HC Wainwright Reiterates Buy Rating on ALNY with Price Target at $510 | ALNY Stock News - GuruFocus
Insider Unloading: Jeffrey V Poulton Sells $695K Worth Of Alnylam Pharmaceuticals Shares - Benzinga
EVP Of Alnylam Pharmaceuticals Makes $607K Sale - Benzinga
Sell Alert: Yvonne Greenstreet Cashes Out $2.16M In Alnylam Pharmaceuticals Stock - Benzinga
Inflation Data: Whats the beta of Alnylam Pharmaceuticals Inc stockM&A Rumor & Verified Short-Term Trading Plans - baoquankhu1.vn
Alnylam Pharmaceuticals, Inc. $ALNY Shares Purchased by Merit Financial Group LLC - Defense World
Eagle Health Investments LP Sells 22,400 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Skandinaviska Enskilda Banken AB publ - MarketBeat
Assessing Alnylam Pharmaceuticals (ALNY) Valuation As Mixed Share Price Returns Meet Bullish Fair Value Models - Yahoo Finance
Alnylam’s First Profitable Year Tests Durability Of TTR RNAi Franchise - simplywall.st
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $429.00 at Canaccord Genuity Group - Defense World
Why Alnylam Pharmaceuticals Stock Was Soaring on Monday - AOL.com
Alnylam EVP Garg sells $695k in stock to cover tax obligations - Investing.com
Jeffrey Poulton Sells 2,242 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Tolga Tanguler Sells 1,959 Shares - MarketBeat
Yvonne Greenstreet Sells 6,958 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Pushkal Garg Sells 2,242 Shares - MarketBeat
Alnylam shares jump as investors focus on profitability and upbeat 2026 revenue outlook - Quiver Quantitative
ALNY: Freedom Capital Markets Upgrades Rating Despite Lower Pric - GuruFocus
Alnylam: Strong Amvuttra Outperformance and High-Value Pipeline Optionality Support Buy Rating - TipRanks
ALNY: Canaccord Genuity Raises Price Target in Latest Analyst Up - GuruFocus
Canaccord Genuity Group Forecasts Strong Price Appreciation for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock - MarketBeat
Alnylam stock rating upgraded at Freedom Capital on AMVUTTRA growth By Investing.com - Investing.com UK
Alnylam Pharmaceuticals Inc (ALNY) 財務データ
収益
当期純利益
現金流量
EPS
Alnylam Pharmaceuticals Inc (ALNY) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Garg Pushkal | EVP Chief R&D |
Feb 13 '26 |
Sale |
310.08 |
2,242 |
695,201 |
24,848 |
| Greenstreet Yvonne | Chief Executive Officer |
Feb 13 '26 |
Sale |
310.08 |
6,958 |
2,157,542 |
85,662 |
| Tanguler Tolga | EVP, Chief Commercial Officer |
Feb 13 '26 |
Sale |
310.08 |
1,959 |
607,448 |
31,769 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Feb 17 '26 |
Sale |
331.96 |
2,041 |
677,532 |
21,264 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Feb 13 '26 |
Sale |
310.08 |
1,959 |
607,448 |
23,305 |
| Poulton Jeffrey V. | EVP, Chief Financial Officer |
Feb 13 '26 |
Sale |
310.08 |
2,242 |
695,201 |
59,802 |
0.60%
1.31%
大文字化:
|
ボリューム (24 時間):